Caliway Biopharmaceuticals C, TW0006919004

Caliway advances CBL-514: 69.60 percent data matter for Caliway Biopharmaceuticals C stock

Published on 10/23/2026 at 09:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Phase 3 recruitment follows October 2 data showing 69.60 percent response versus 0 percent placebo. November 11 results test Caliway Biopharmaceuticals C stock.

Phase 3 and reporting date

On October 22, 2026, Caliway presented CBL-514 data showing a 69.60 percent response.
Phase 2 data showed a 12.01 percent reduction in visceral fat versus a 5.68 percent increase with placebo.
Caliway's next reporting date is November 11, 2026.
The Taiwan-listed stock had a TWD 114.9 billion market capitalization on October 22, 2026.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals C stock is tied to a new phase 3 development milestone after CBL-514 produced a 69.60 percent response in phase 2 data. On October 22, 2026, Pharmaphorum reported that Caliway was preparing two placebo-controlled phase 3 trials after the result, giving the company a clinical catalyst rather than a commercial revenue event.

CBL-514 moves into phase 3

The core result came from participants treated with CBL-514 for abdominal fat reduction. On October 2, 2026, Caliway Biopharmaceuticals said 69.60 percent of treated participants reduced subcutaneous fat volume by at least 150 mL at the eight-week follow-up, compared with 0 percent in the placebo group. The company also reported a 12.01 percent reduction in visceral fat four weeks after the final treatment, while the placebo group recorded a 5.68 percent increase.

The comparison gives investors a clearer measure of the program's clinical signal. The between-group difference in the visceral-fat analysis was 17.69 percentage points, while the first phase 3 study is designed to enroll approximately 320 participants. Recruitment for the first of two trials is under way, and the program is aimed at nonsurgical abdominal fat reduction.

What does the next report add?

Caliway's near-term calendar points to November 11, 2026, when the company is scheduled to release its next report, according to Investing.com. The latest reported quarter ended June 2026 and included TWD 3.57 million in revenue, TWD 222.52 million in net loss and adjusted earnings per share of minus TWD 0.14, figures that keep the clinical pipeline ahead of commercial scale.

Three dated development milestones

On September 23, 2026, Caliway announced first dosing in SUPREME-01, a global phase 3 trial expected to enroll 320 participants, according to Caliway Biopharmaceuticals. On October 2, 2026, the company published the 69.60 percent subcutaneous-fat response and the 12.01 percent visceral-fat reduction. On October 22, 2026, Pharmaphorum linked those results to the preparation of two phase 3 trials.

Stock context and valuation

The Taiwan-listed stock was last quoted at TWD 73.80 on October 22, 2026 at 2:39 p.m. CST. Its 52-week range was TWD 73.80 to TWD 188.00, and its market capitalization was TWD 114.9 billion on that date. The market picture therefore remains closely tied to clinical execution and the next reporting date rather than to recurring product sales.